Peter Greenleaf, Aurinia CEO

March 3, 2022 01:09 PM EST

Aurinia faces choppy waters amid lower-than-expected 2022 guidance and patent challenge on Lupkynis

Beth Snyder Bulik

Senior Editor

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

ENDPOINTS CAREERS

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

view job offer post your job now

TRENDING NOW

A new dawn for psychedelics? Compass could be the first to find out

Weeks after TIGIT fail, iTeos decides to wind down

The fate of Moderna’s next-gen Covid shot looms large after a flurry of policy changes

Updated: MD Anderson-allied investment firm targets $250M for second cancer biotech fund

GSK, Spero report Phase 3 win for UTI antibiotic; Spero's stock soars

sponsored

From weeks to days: how Aizon Intelligent Agents transform pharma validation